A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease

M Farlow, R Anand, J Messina Jr, R Hartman… - European …, 2000 - karger.com
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713;
Exelon®), in patients with mild to moderately severe Alzheimer's disease was evaluated in a …
被引用次数：439 相关文章

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease

M Farlow, R Anand, J Messina Jr… - European …, 2000 - pubmed.ncbi.nlm.nih.gov
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713;
Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a …

[引用][C] A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease

M FARLOW, R ANAND, JJR MESSINA… - European …, 2000 - pascal-francis.inist.fr
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe
Alzheimer's disease CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer's Disease

M Farlow, R Anand, J Messina Jr, R Hartman… - European …, 2000 - cir.nii.ac.jp
抄録< jats: p> The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate
(ENA 713; Exelon®), in patients with mild to moderately severe Alzheimer's disease was …

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer's Disease

M Farlow, R Anand, J Messina Jr, R Hartman… - European …, 2000 - karger.com
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713;
Exelon®), in patients with mild to moderately severe Alzheimer's disease was evaluated in a …

A 52-week study of the efficacy of rivastigmine in patient with mild to moderatley severe Alzheimer's disease

M Farlow, R Anand, J Messina Jr… - European …, 2000 - search.proquest.com
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713;
Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a …

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer's Disease.

M Farlow, R Anand, J Messina Jr… - European …, 2000 - search.ebscohost.com
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713;
Exelon [sup®]), in patients with mild to moderately severe Alzheimer's disease was …

[引用][C] A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease

M FARLOW, R ANAND, JJR MESSINA, R HARTMAN… - European …, 2000 - Karger